| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.01. | BONYF: bonyf - A Year of Certification, Innovation and Commercial Acceleration | 1 | Euronext | ||
| 22.12.25 | BONYF: Company Update on Market Trading Dynamics and Business Fundamentals | 1 | Euronext | ||
| 24.11.25 | BONYF: PerioCream becomes the most in-demand bonyf innovation | 2 | Euronext | ||
| BONYF Aktie jetzt für 0€ handeln | |||||
| 15.10.25 | bonyf AG receives the EU-MDR Certification Class IIa for PerioCream | 449 | Dow Jones News | DJ bonyf AG receives the EU-MDR Certification Class IIa for PerioCream
bonyf NV / Key word(s): Product Launch/Incoming Orders
bonyf AG receives the EU-MDR Certification Class IIa for PerioCream... ► Artikel lesen | |
| 15.09.25 | bonyf NV Showcases Innovative Product Portfolio at ExpoPharm 2025 in Düsseldorf | 455 | Dow Jones News | DJ bonyf NV Showcases Innovative Product Portfolio at ExpoPharm 2025 in Düsseldorf
bonyf NV / Key word(s): Conference/Corporate Action
bonyf NV Showcases Innovative Product Portfolio at ExpoPharm... ► Artikel lesen | |
| 05.09.25 | bonyf NV Cancels Planned Capital Increase Following Positive Strategic Developments | 341 | Dow Jones News | DJ bonyf NV Cancels Planned Capital Increase Following Positive Strategic Developments
bonyf NV / Key word(s): Financing/Corporate Action
bonyf NV Cancels Planned Capital Increase Following Positive... ► Artikel lesen | |
| 11.08.25 | Periocream: The Future Commercial Winner for bonyf | 476 | Dow Jones News | DJ Periocream: The Future Commercial Winner for bonyf
bonyf NV / Key word(s): Market Launch/Development of Sales
Periocream: The Future Commercial Winner for bonyf
11-Aug-2025 / 15:16 CET/CEST... ► Artikel lesen | |
| 14.07.25 | bonyf Reaffirms Its Long-Term Vision Amid Short-Term Market Volatility | 416 | Dow Jones News | DJ bonyf Reaffirms Its Long-Term Vision Amid Short-Term Market Volatility
bonyf NV / Key word(s): Corporate Action/Results Forecast
bonyf Reaffirms Its Long-Term Vision Amid Short-Term Market Volatility... ► Artikel lesen | |
| 30.06.25 | bonyf NV: Annual Results 2024 | 682 | Dow Jones News | DJ Annual Results 2024
bonyf NV / Key word(s): Annual Results/Financing
Annual Results 2024
30-Jun-2025 / 21:18 CET/CEST
=----------------------------------------------------------------------------------------------------------------------... ► Artikel lesen | |
| 03.06.25 | bonyf Welcomes Group Pharmaceuticals as Strategic Stakeholder to Drive Growth in India | 548 | Dow Jones News | DJ bonyf Welcomes Group Pharmaceuticals as Strategic Stakeholder to Drive Growth in India
bonyf NV / Key word(s): Capital Increase/Expansion
bonyf Welcomes Group Pharmaceuticals as Strategic Stakeholder... ► Artikel lesen | |
| 15.05.25 | bonyf NV Announces First Exports to the United States with Honest Pharma, Marking a Key Milestone in USA Growth Strategy | 624 | Dow Jones News | DJ bonyf NV Announces First Exports to the United States with Honest Pharma, Marking a Key Milestone in USA Growth Strategy
bonyf NV / Key word(s): Expansion/Market Launch
bonyf NV Announces First... ► Artikel lesen | |
| 08.04.25 | bonyf Advances to Phase 3 in the Development of Alginate-Organic Denture Fixative Cream | 507 | Dow Jones News | DJ bonyf Advances to Phase 3 in the Development of Alginate-Organic Denture Fixative Cream
bonyf NV / Key word(s): Research Update/Product Launch
bonyf Advances to Phase 3 in the Development of... ► Artikel lesen | |
| 13.03.25 | bonyf recently secures its EU Patent, US patent pending, for PerioTabs & PerioCream, launch in March 2025 at the IDS Cologne | 523 | Dow Jones News | DJ bonyf recently secures its EU Patent, US patent pending, for PerioTabs® & PerioCream, launch in March 2025 at the IDS Cologne
bonyf NV / Key word(s): Product Launch/Patent
bonyf recently secures... ► Artikel lesen | |
| 18.02.25 | bonyf Announces Plans for Dual Listing on Nasdaq and Euronext Paris with a Five-Step Strategy | 573 | Dow Jones News | DJ bonyf Announces Plans for Dual Listing on Nasdaq and Euronext Paris with a Five-Step Strategy
bonyf NV / Key word(s): Corporate Action/Funds
bonyf Announces Plans for Dual Listing on Nasdaq... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SIEMENS HEALTHINEERS | 41,400 | -2,82 % | HV-Termine: Hauptversammlungen bei Adv. Blockchain, Aurubis, Fortec, Schott, Siemens, Healthineers, Stabilus, TUI | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 40,640 | +0,40 % | Fresenius Medical Care: Ein Neuanfang nach turbulenten Zeiten? | ||
| FRESENIUS | 49,760 | +1,06 % | JEFFERIES stuft Fresenius SE auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Fresenius mit einem Kursziel von 55 Euro auf "Buy" belassen. Die Bad Homburger seien in Verjüngungskur, und der Markt preise... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 28,740 | +4,89 % | PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance | SAN JOSE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 39,680 | +3,44 % | BrightSpring Health Services, Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026 | ||
| CARL ZEISS MEDITEC | 27,520 | +0,66 % | BARCLAYS stuft CARL ZEISS MEDITEC AG auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Carl Zeiss Meditec von 49 auf 32 Euro gesenkt und die Aktien von "Overweight" auf "Equal Weight" abgestuft. Nur... ► Artikel lesen | |
| HEARTFLOW | 27,690 | +6,54 % | Heartflow, Inc.: Heartflow FFRCT Analysis Delivers Prognostic Power and Significant Cost Savings in New Analyses of Over 90,000 Patients with Coronary Artery Disease | Lesion-specific FFRCT predicts individual cardiovascular outcomes and delivers greater-than-modeled cost savings for real-world population in FISH&CHIPS analyses from England's National Health ServiceMOUNTAIN... ► Artikel lesen | |
| GENEDX | 84,35 | +0,32 % | GeneDx to Participate in Upcoming Investor Conferences | GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences:
Stifel... ► Artikel lesen | |
| PRIVIA HEALTH GROUP | 21,990 | +2,23 % | Privia Health Group, Inc.: Privia Health Reports Third Quarter 2025 Financial Results | Very Strong Third Quarter and Year-to-Date Performance Across the BusinessNet Income +94.1% and Adjusted EBITDA +61.6% compared to 3Q'24Implemented Providers +13.1% and Practice Collections +27.1%... ► Artikel lesen | |
| GERRESHEIMER | 25,660 | +1,99 % | JEFFERIES stuft GERRESHEIMER AG auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Gerresheimer mit einem Kursziel von 34,10 Euro auf "Buy" belassen. Analyst James Vane-Tempest zählt den Spezialverpackungshersteller... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 21,750 | +2,84 % | 6 Analysts Have This To Say About Alignment Healthcare | ||
| PROGYNY | 21,960 | +0,18 % | Progyny, Inc. Announces Third Quarter 2025 Results | Reports Revenue of $313.3 Million, Reflecting 9.3% GrowthRaises Full Year Guidance to Reflect Continued Strength in Member EngagementSelling Season Yields Over 80 New Clients, 900,000 New Lives, and... ► Artikel lesen | |
| HIMS & HERS HEALTH | 19,500 | +0,15 % | BREAKING: Hims & Hers verschärft Preisdruck bei Novo Nordisk - Aktie beschleunigt Talfahrt | Der dänische Biopharma-Riese ist erst seit wenigen Wochen mit seinem Appetitzügler Wegovy als Tablette auf dem US-Markt und sieht sich einem massiven Preisdruck ausgesetzt. Das Telehealth-Unternehmen... ► Artikel lesen | |
| UNITEDHEALTH | 232,15 | -0,77 % | UnitedHealth: Das sieht gar nicht gut aus | Der enttäuschende Ausblick, den UnitedHealth dem Kapitalmarkt vor Kurzem an die Hand gegeben hat, und maue Aussichten für 2027 hinterlassen weitere Spuren im Aktienkurs des größten US-Krankenversicherers.... ► Artikel lesen | |
| RXSIGHT | 8,390 | +7,29 % | RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial Officer | ALISO VIEJO, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following... ► Artikel lesen |